Development of a high-throughput screen for soluble epoxide hydrolase inhibition

Analytical Biochemistry

Volumn 355, Issue 1, 2006, Pages 71-80

  Wolf, Nicola M ^a,b   Morisseau, Christophe ^b   Jones, Paul D ^b   Hock, Bertold ^a   Hammock, Bruce D ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fluorescent assay; High throughput screen; Soluble epoxide hydrolase inhibition; Cyanoester

Indexed keywords

DRUG DELIVERY; FLUORESCENT SCREENS; HYDROLASES; MAMMALS; SOLUBILITY;

AQUEOUS STABILITY; CARDIO-VASCULAR DISEASE; CHEMICAL INHIBITION; COMPOUND LIBRARIES; EPOXIDE HYDROLASES; FLUORESCENT ASSAYS; HIGH-THROUGHPUT SCREENS; RELATIVE STANDARD DEVIATIONS;

ENZYME INHIBITION;

(3 PHENYLOXIRANYL)ACETIC ACID CYANO(6 METHOXYNAPHTHALEN 2 YL)METHYL ESTER; EPOXIDE; EPOXIDE HYDROLASE; ESTER DERIVATIVE; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CONCENTRATION (PARAMETERS); ENZYME INHIBITION; ENZYME SUBSTRATE; HIGH THROUGHPUT SCREENING; INCUBATION TIME; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RELIABILITY; REPRODUCIBILITY; ROOM TEMPERATURE; SENSITIVITY AND SPECIFICITY; SOLUBILITY; VALIDATION STUDY;

ANIMALIA; MAMMALIA;

EID: 33745918021     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2006.04.045     Document Type: Article

References (40)

1. Oesch F. Mammalian epoxide hydrases: inducible enzymes catalysing the inactivation of carcinogenic and cytotoxic metabolites derived from aromatic and olefinic compounds. Xenobiotica 3 (1973) 305-340
2. Harder D.R., Campbell W.B., and Roman R.J. Role of cytochrome P-450 enzymes and metabolites of arachidonic acid in the control of vascular tone. J. Vasc. Res. 32 (1995) 79-92
3. Campbell W.B., Gebremedhin D., Pratt P.F., and Harder D.R. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ. Res. 78 (1996) 415-423
4. Node K., Huo Y., Ruan X., Yang B., Spiecker M., Ley K., Zeldin D.C., and Liao J.K. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285 (1999) 1276-1279
5. Newman J.W., Morisseau C., and Hammock B.D. Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog. Lipid Res. 44 (2005) 1-51
6. Imig J.D., Zhao X., Capdevila J.H., Morisseau C., and Hammock B.D. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39 (2002) 690-694
7. Yu Z., Xu F., Huse L.M., Morisseau C., Draper A.J., Newman J.W., Parker C., Graham L., Engler M.M., Hammock B.D., Zeldin D.C., and Kroetz D.L. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ. Res. 87 (2000) 992-998
8. Imig J.D., Zhao X., Zaharis C.Z., Olearczyk J.J., Pollock D.M., Newman J.W., Kim I.H., Watanabe T., and Hammock B.D. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 46 (2005) 975-981
9. Schmelzer K.R., Kubala L., Newman J.W., Kim I.H., Eiserich J.P., and Hammock B.D. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc. Natl. Acad. Sci. USA 102 (2005) 9772-9777
10. Smith K.R., Pinkerton K.E., Watanabe T., Pedersen T.L., Ma S.J., and Hammock B.D. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc. Natl. Acad. Sci. USA 102 (2005) 2186-2191
11. Zhao X., Yamamoto T., Newman J.W., Kim I.H., Watanabe T., Hammock B.D., Stewart J., Pollock J.S., Pollock D.M., and Imig J.D. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J. Am. Soc. Nephrol. 15 (2004) 1244-1253
12. Dorrance A.M., Rupp N., Pollock D.M., Newman J.W., Hammock B.D., and Imig J.D. An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 46 (2005) 842-848
13. Morisseau C., Goodrow M.H., Dowdy D., Zheng J., Greene J.F., Sanborn J.R., and Hammock B.D. Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc. Natl. Acad. Sci. USA 96 (1999) 8849-8854
14. Nakagawa Y., Wheelock C.E., Morisseau C., Goodrow M.H., Hammock B.G., and Hammock B.D. 3-D QSAR analysis of inhibition of murine soluble epoxide hydrolase (MsEH) by benzoylureas, arylureas, and their analogues. Bioorg. Med. Chem. Lett. 8 (2000) 2663-2673
15. Morisseau C., Goodrow M.H., Newman J.W., Wheelock C.E., Dowdy D.L., and Hammock B.D. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem. Pharmacol. 63 (2002) 1599-1608
16. McElroy N.R., Jurs P.C., Morisseau C., and Hammock B.D. QSAR and classification of murine and human soluble epoxide hydrolase inhibition by urea-like compounds. J. Med. Chem. 46 (2003) 1066-1080
17. Kim I.H., Morisseau C., Watanabe T., and Hammock B.D. Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. J. Med. Chem. 47 (2004) 2110-2122
18. Kim I.H., Heirtzler F.R., Morisseau C., Nishi K., Tsai H.J., and Hammock B.D. Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J. Med. Chem. 48 (2005) 3621-3629
19. Morisseau C., and Hammock B.D. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 311-333
20. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46 (2001) 3-26
21. Watanabe T., Schulz D., Morisseau C., and Hammock B.D. High-throughput pharmacokinetic method: cassette dosing in mice associated with minuscule serial bleedings and LC-MS-MS analysis. Anal. Chim. Acta 559 (2006) 37-44
22. Dietze E.C., Kuwano E., and Hammock B.D. Spectrophotometric substrates for cytosolic epoxide hydrolase. Anal. Biochem. 216 (1994) 176-187
23. Borhan B., Mebrahtu T., Nazarian S., Kurth M.J., and Hammock B.D. Improved radiolabeled substrates for soluble epoxide hydrolase. Anal. Biochem. 231 (1995) 188-200
24. Jones P.D., Wolf N.M., Morisseau C., Whetstone P., Hock B., and Hammock B.D. Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies. Anal. Biochem. 343 (2005) 66-75
25. Wixtrom R.N., Silva M.H., and Hammock B.D. Affinity purification of cytosolic epoxide hydrolase using derivatized epoxy-activated Sepharose gels. Anal. Biochem. 169 (1988) 71-80
26. Beetham J.K., Tian T., and Hammock B.D. cDNA cloning and expression of a soluble epoxide hydrolase from human liver. Arch. Biochem. Biophys. 305 (1993) 197-201
27. Venhorst J., Onderwater R.C., Meerman J.H., Vermeulen N.P., and Commandeur J.N. Evaluation of a novel high-throughput assay for cytochrome P450 2D6 using 7-methoxy-4-(aminomethyl)-coumarin. Eur. J. Pharm. Sci. 12 (2000) 151-158
28. Marks B.D., Goossens T.A., Braun H.A., Ozers M.S., Smith R.W., Lebakken C., and Trubetskoy O.V. High-throughput screening assays for CYP2B6 metabolism and inhibition using fluorogenic vivid substrates. AAPS Pharm. Sci. 5 (2003) e18
29. Soriano A., Radice A.D., Herbitter A.H., Langsdorf E.F., Stafford J.M., Chan S., Wang S., Liu Y.H., and Black T.A. Escherichia coli acetyl-coenzyme A carboxylase: characterization and development of a high-throughput assay. Anal. Biochem. 349 (2006) 268-276
30. Morisseau C., Du G., Newman J.W., and Hammock B.D. Mechanism of mammalian soluble epoxide hydrolase inhibition by chalcone oxide derivatives. Arch. Biochem. Biophys. 356 (1998) 214-228
31. Morisseau C., Beetham J.K., Pinot F., Debernard S., Newman J.W., and Hammock B.D. Cress and potato soluble epoxide hydrolases: purification, biochemical characterization, and comparison to mammalian enzymes. Arch. Biochem. Biophys. 378 (2000) 321-332
32. Zhang J.H., Chung T.D., and Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4 (1999) 67-73
33. Draper A.J., and Hammock B.D. Soluble epoxide hydrolase in rat inflammatory cells is indistinguishable from soluble epoxide hydrolase in rat liver. Toxicol. Sci. 50 (1999) 30-35
34. Newman J.W., Morisseau C., Harris T.R., and Hammock B.D. The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. Proc. Natl. Acad. Sci. USA 100 (2003) 1558-1563
35. Arand M., Cronin A., Adamska M., and Oesch F. Epoxide hydrolases: structure, function, mechanism, and assay. Methods Enzymol. 400 (2005) 569-588
36. Shan G., and Hammock B.D. Development of sensitive esterase assays based on α-cyano-containing esters. Anal. Biochem. 299 (2001) 54-62
37. Wheelock C.E., Wheelock Å.M., Zhang R., Stok J.E., Morisseau C., Le Valley S.E., Green C.E., and Hammock B.D. Evaluation of α-cyanoesters as fluorescent substrates for examining interindividual variation in general and pyrethroid-selective esterases in human liver microsomes. Anal. Biochem. 315 (2003) 208-222
38. Zhang R., Kang K.-D., Shan G., and Hammock B.D. Design, synthesis, and evaluation of novel P450 fluorescent probes bearing α-cyanoether. Tetrahedron Lett. 44 (2003) 4331-4334
39. Kang K.-D., Jones P.D., Huang H., Zhang R., Mostovich L.A., Wheelock C.E., Watanabe T., Gulyaeva L.F., and Hammock B.D. Evaluation of α-cyano ethers as fluorescent substrates for assay of cytochrome P450 enyzme activity. Anal. Biochem. 344 (2005) 183-192
40. de Vries E.J., and Janssen D.B. Biocatalytic conversion of epoxides. Curr. Opin. Biotechnol. 14 (2003) 414-420